Subcutaneous vs Intramuscular Testosterone

Creator: Peptide Me Editorial Team
Published: 2026-06-24

Subcutaneous and intramuscular testosterone deliver the same drug to the same bloodstream by two different doors. The published data says exposure is broadly comparable — what actually differs is comfort, needle size, site reactions, and how easy the shot is to do yourself.

PMWritten byPeptide Me Editorial Team11 min read · Updated Jun 2026 · Reviewed against 11 sources

TL;DR

Across the available studies, subcutaneous (SubQ) and intramuscular (IM) injection of the same testosterone ester at the same dose produce comparable serum testosterone exposure — one crossover study measured mean AUC of 1.7 vs 1.9 nmol·days/L/mg between the two routes, with no statistically significant difference.
The reliable difference is tolerability, not blood levels: patients consistently report less pre-injection anxiety and less injection pain with SubQ, and in one cohort all 22 patients who switched from IM to SubQ preferred the SubQ route.
SubQ is not automatically better for every product. Long-acting testosterone undecanoate in a 4 mL castor-oil vehicle was more painful 24 hours after a SubQ shot than after an IM shot, and the majority of men in that trial still preferred IM.
Route is a prescriber's decision, not a self-directed swap. Depo-Testosterone is labeled for IM use only, while XYOSTED is FDA-approved specifically for weekly subcutaneous abdominal injection — the label you are holding matters.

Every injectable testosterone protocol has to answer one mechanical question before anything else: how deep does the needle go? Intramuscular (IM) injection places the oil into muscle tissue — the ventrogluteal hip, deltoid, or vastus lateralis. Subcutaneous (SubQ) injection places it in the fat layer just under the skin, usually the abdomen or the front of the thigh. IM has roughly eight decades of clinical history behind it; SubQ is the newer option that has gained ground fast, mostly because it is easier to do to yourself.¹ This guide compares the two on the things that actually differ: absorption, dose, comfort, side effects, and what a switch involves. For the mechanics of performing either injection, see our step-by-step testosterone injection guide, and for the wider picture of starting therapy, the TRT hub.

What physically changes between the two routes

Muscle is densely vascular; subcutaneous fat is not. Nursing pharmacology texts describe subcutaneous tissue as having comparatively few blood vessels, which is precisely why medications deposited there are absorbed at a slower, more sustained rate than the same drug placed in muscle.² That single physiological fact drives most of the differences people notice. A SubQ depot releases its ester into circulation more gradually, which in theory blunts the early spike. An IM depot sits in richly perfused tissue and starts unloading sooner.

The equipment follows from the depth. IM injection requires a needle long enough to actually reach muscle — typically 1 to 1.5 inches at 22–25 gauge, with the correct length depending on the site and the person's body composition, since a needle that is too short simply deposits the dose into fat instead.³ SubQ injection uses a much shorter, finer needle (commonly 25–27 gauge, 1/2 to 5/8 inch) inserted at 45 to 90 degrees depending on how much tissue is pinched.² That difference in hardware is not cosmetic — it is the main reason many patients find SubQ dramatically less intimidating to self-administer.

Absorption and blood levels: what the studies actually found

The headline finding across the literature is that the theoretical difference in absorption speed does not translate into meaningfully different testosterone exposure. A 2022 systematic review in the Journal of Clinical Endocrinology & Metabolism concluded that subcutaneous testosterone therapy, given at doses similar to those used intramuscularly, produces comparable pharmacokinetics and comparable mean serum testosterone levels — and that with appropriate training, patients can self-administer testosterone esters subcutaneously safely and with less discomfort than the IM route.¹

The most direct head-to-head evidence comes from a crossover pilot study in which 14 transgender men on stable testosterone therapy did three weeks of intramuscular injections followed by eight weeks of subcutaneous injections. Total testosterone exposure was statistically indistinguishable between the routes — mean AUC of 1.7 ± 0.6 nmol·days/L/mg subcutaneously versus 1.9 ± 0.6 nmol·days/L/mg intramuscularly. Hemoglobin and ALT were unchanged from baseline to study end on either route.⁴ The differences that did reach significance were all about the patient experience, not the pharmacology.

Stability between doses looks similar too. A pharmacokinetic analysis of 11 patients on weekly subcutaneous testosterone cypionate (50–100 mg, median 75 mg) found mean total and free testosterone stayed well within the normal male range across the entire dosing interval, averaging 627 ± 206 ng/dL, with only a minor dip in the final two days before the next injection.⁵ The authors noted a similar pattern has been reported for weekly IM injections — so neither route has a monopoly on flat levels. A phase II study of weekly subcutaneous testosterone enanthate reached normal average serum testosterone across the full 168-hour dosing interval at both 50 mg and 100 mg, with dose-proportional exposure and "low variation relative to 200-mg IM" in the reference group¹¹ — though that comparison confounds route with dose size, since 200 mg is a much larger bolus than 50–100 mg. Injection frequency is the bigger lever on how flat your curve is, which is the subject of our TRT microdosing guide, and you can model how any ester and interval combine using the concepts in half-life, explained.

Attribute	Subcutaneous (SubQ)	Intramuscular (IM)
Tissue targeted	Fat layer beneath the skin	Muscle body
Common sites	Abdomen (avoiding a 2-inch circle around the navel), front of thigh	Ventrogluteal hip, deltoid, vastus lateralis
Typical needle	25–27G, 1/2–5/8 inch	22–25G, 1–1.5 inch
Angle	45–90°, depending on pinch	90°
Absorption	Slower, sustained (fewer blood vessels)	Faster onset from well-perfused muscle
Measured exposure	AUC 1.7 ± 0.6 nmol·days/L/mg⁴	AUC 1.9 ± 0.6 nmol·days/L/mg⁴ (not significantly different)
Reported comfort	Lower pre-injection anxiety and injection pain⁴	Higher on both measures for short/medium esters
Ease of self-injection	Easier for most patients¹	Harder to reach some sites alone
FDA-labeled example	XYOSTED (testosterone enanthate autoinjector), abdomen only⁶	Depo-Testosterone (testosterone cypionate), deep IM only⁷

Does the dose change when you switch routes?

This is the question most people get wrong, and the honest answer is that it depends on the ester and on your prescriber's judgment — not on a fixed conversion factor. For long-acting testosterone undecanoate, a randomized crossover study explicitly concluded that the subcutaneous route is an alternative to IM "without a need to change dose."⁸ For weekly cypionate or enanthate, the picture is less tidy: the 2022 review found comparable levels at similar doses¹, while the practical experience in some clinics has been that patients settle at the lower end of the dose range on SubQ. In the largest SubQ cohort published, 63 patients started at 50 mg weekly and were titrated across a 50–150 mg range, with a median landing dose of 75–80 mg.⁹

What that means practically: treat a route change as a change that requires re-titration against labs, exactly like a dose change would. The Endocrine Society's clinical practice guideline anchors testosterone dosing to scheduled monitoring and a mid-normal-range target rather than to how a protocol feels in week two, and that framing applies to a route change as much as to a dose increase.¹⁰ Do not assume your existing number transfers untouched, and do not adjust it yourself on the assumption that it won't. Our TRT bloodwork guide covers which markers to recheck and when.

Comfort, convenience, and adherence

This is where SubQ has its clearest advantage, and it is not a small one. In the crossover pilot, subcutaneous injection scored lower on pre-injection anxiety, pain during the injection, and pain after the injection.⁴ In the 63-patient cohort, 22 participants had previously been on intramuscular therapy and switched; all 22 preferred the subcutaneous route, 20 of them markedly so.⁹ The review literature makes the same point from the other direction — IM injections "are difficult to self-administer and associated with some discomfort," and easier self-administration has the potential to improve adherence.¹

Adherence is the part worth dwelling on. A protocol you dread is a protocol you postpone, and postponed injections show up in your trough levels and in how you feel by the end of the week. If the difficulty of reaching a ventrogluteal site alone is what keeps pushing your shot from Monday to Wednesday, that is a clinical problem worth raising with your prescriber, not a discipline failure. Our injection sites and rotation guide maps out which sites are realistically self-accessible on each route.

Track your TRT protocol in Peptide Me

Log every shot, rotate injection sites, and chart your bloodwork over time.

Download on theApp Store

Side effects and site reactions

Local reactions occur on both routes and are usually minor. In the 63-patient subcutaneous cohort, 9 of 63 patients reported local reactions, all described as minor and transient.⁹ In the smaller weekly-cypionate pharmacokinetic series, no adverse local reactions occurred at all.⁵ Some patients on SubQ report small firm nodules or itching at the site — repeated deposits in one spot can thicken subcutaneous tissue (lipohypertrophy), which is why rotation guidance for SubQ injection specifically exists.²

Systemic effects are properties of testosterone itself, not of the door it came through. The FDA label for XYOSTED — the subcutaneous autoinjector — instructs clinicians to monitor hematocrit roughly every three months because testosterone raises red cell mass; hematocrit rose to 55% or higher in 4.2% of trial patients, and polycythemia was reported in 1.8%.⁶ The same label notes testosterone can raise blood pressure, measured an average systolic/diastolic increase of about 3.9/1.5 mm Hg, and advises against use in uncontrolled hypertension.⁶ None of those cautions disappear because you switched to a shorter needle.

◑ Limited human dataEvidence grade: the SubQ pharmacokinetic data is consistent but comes from small studies — 11, 14, 20, and 63 patients in the trials cited here, several of them in transgender men rather than hypogonadal cisgender men. The 2022 systematic review states plainly that studies directly comparing the safety of SubQ versus IM testosterone are still desirable. "Comparable exposure" is well supported; "equivalent long-term safety" has not been formally demonstrated either way.

Where SubQ is not the easy win: long-acting undecanoate

The blanket claim that subcutaneous injection hurts less breaks down for large-volume, long-acting products. A randomized crossover study injected 1000 mg of testosterone undecanoate in 4 mL of castor oil by both routes in 20 men. Pain was greater 24 hours after the subcutaneous injection than after the intramuscular one, and when asked to choose, 11 preferred IM, 6 preferred SubQ, and 3 had no preference.⁸ Pharmacokinetically the routes were close: subcutaneous injection produced a later peak (8.0 vs 3.3 days) but no significant difference in model-predicted peak concentration (8.4 vs 9.6 ng/mL), and testosterone, DHT, and estradiol profiles did not differ substantially by route.⁸

The lesson generalizes: volume matters. Subcutaneous tissue tolerates small volumes of thin oil well and large volumes of viscous oil poorly. A 0.3 mL weekly cypionate microdose and a 4 mL quarterly undecanoate depot are not the same proposition just because both are testosterone.

What your label actually says

Route is not purely a preference question, because the approved labeling differs by product. Depo-Testosterone (testosterone cypionate) is labeled for intramuscular use, given deep into muscle and never intravenously.⁷ XYOSTED (testosterone enanthate) is the opposite case — it is an FDA-approved autoinjector specifically for subcutaneous injection in the abdominal region only, at a starting dose of 75 mg once weekly, with intramuscular and intravascular administration to be avoided.⁶ When a clinician prescribes cypionate for subcutaneous use, that is a deliberate off-label decision they are making and monitoring. It is a reasonable and increasingly common one¹ — but it is theirs to make, not something to improvise from a forum post.

How to switch routes safely

Raise it as a clinical question, not a done deal — bring the specific reason (injection anxiety, site pain, difficulty self-injecting, poor adherence) rather than a request for a protocol.
Confirm whether your dose stays the same or is re-titrated; for undecanoate the published guidance is no dose change<sup>8</sup>, for weekly esters it is a case-by-case judgment.
Get the new supplies right: a shorter, finer needle for SubQ, and a concentration that makes the smaller volume easy to measure accurately.
Ask for hands-on instruction on the new technique before your first solo attempt — pinch depth and angle are different from IM and are easy to get wrong from a written description.
Set up a site rotation across the abdomen and thighs from day one, rather than reusing one convenient spot.
Hold the new route unchanged for roughly six to eight weeks, then recheck trough total testosterone, free testosterone or SHBG, estradiol, and hematocrit.
Judge the switch on those numbers plus how you feel across the whole week — not on the first two or three injections.

Which route is right for you

If your main complaint about TRT is the injection itself — the needle length, the anxiety, the soreness afterwards, or needing help to reach the site — the evidence supports discussing SubQ, because that is exactly the dimension on which it consistently wins.^1,4,9 If you are on a large-volume long-acting depot, or you are already comfortable with your IM routine and your labs look good, there is no pharmacological reason to change; the exposure data does not promise you better levels.^4,8 And if you are just starting therapy, the practical question is usually which route you will actually keep doing correctly for years, since adherence beats theoretical optimization every time. Our TRT results timeline covers what to expect once you're settled on either route.

Whichever door you use, the tracking problem is the same: your levels only make sense next to your dose, your route, your site, and how long it had been since your last shot. Peptide Me lets you log route and site alongside each dose, keep bloodwork on the same timeline, and see whether a route change actually moved your trough — instead of trying to remember three months later. Explore the rest of our injection and dosing material in the TRT hub.

Disclaimer: this article compares injection routes and is not medical advice. Testosterone cypionate and enanthate are prescription, Schedule III controlled medications. Your route, dose, injection frequency, and any change to any of them should come from the clinician monitoring your bloodwork. If anything here conflicts with what your prescriber told you, follow your prescriber.

⚠︎Educational information only — not medical advice. Testosterone is a prescription medication; discuss any route or dose change with a licensed clinician.

FAQ

On the available evidence, yes in terms of blood levels. A crossover pilot study found no statistically significant difference in total testosterone exposure between routes (mean AUC 1.7 vs 1.9 nmol·days/L/mg), and a 2022 systematic review concluded that subcutaneous dosing at similar doses produces comparable pharmacokinetics and mean serum testosterone. The studies are small, though, and no trial has directly compared long-term safety between the two routes.

Not necessarily, and there's no fixed conversion factor. For long-acting testosterone undecanoate, the published crossover study concluded no dose change is needed. For weekly cypionate or enanthate the review evidence shows comparable levels at similar doses, though some clinics find patients settle at the lower end of the range. Treat a route switch like a dose change: re-check labs about six to eight weeks later rather than assuming your number transfers unchanged.

For weekly esters, usually yes — patients report lower pre-injection anxiety and less pain both during and after subcutaneous injection, largely because the needle is shorter and finer. The exception is large-volume long-acting undecanoate: in a randomized crossover study, pain 24 hours after a 4 mL subcutaneous injection was greater than after the same dose given intramuscularly, and most participants still preferred the IM route.

Many clinicians prescribe it that way, but note that Depo-Testosterone's FDA label specifies intramuscular use, so subcutaneous cypionate is an off-label route decision your prescriber makes deliberately. XYOSTED (testosterone enanthate) is the product actually FDA-approved for subcutaneous use, and only in the abdominal region. Either way, this is a prescriber decision rather than a self-directed change.

There's no good direct comparison establishing that. Raising red cell mass is an effect of testosterone itself, not of the injection route, and the FDA label for the subcutaneous autoinjector still instructs clinicians to monitor hematocrit roughly every three months — 4.2% of trial patients reached a hematocrit of 55% or higher on it. Monitoring requirements do not relax because you switched routes.

References

Primary sources — PubMed / NEJM / The Lancet.

Figueiredo MG, Gagliano-Jucá T, Basaria S. Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option. J Clin Endocrinol Metab. 2022;107(3):614-626. https://pmc.ncbi.nlm.nih.gov/articles/PMC9006970/
Ernstmeyer K, Christman E, eds. Administration of Parenteral Medications. In: Nursing Skills [Internet]. Chippewa Valley Technical College; 2021. https://www.ncbi.nlm.nih.gov/books/NBK596739/
Polania Gutierrez JJ, Munakomi S. Intramuscular Injection. StatPearls [Internet]. 2023. https://www.ncbi.nlm.nih.gov/books/NBK556121/
Wilson DM, Kiang TKL, Ensom MHH. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. Am J Health Syst Pharm. 2018;75(6):351-358. https://pubmed.ncbi.nlm.nih.gov/29367424/
McFarland J, Craig W, Clarke NJ, Spratt DI. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. J Endocr Soc. 2017;1(8):1095-1103. https://pmc.ncbi.nlm.nih.gov/articles/PMC5686655/
DailyMed. XYOSTED (testosterone enanthate) injection, solution — Prescribing Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81
DailyMed. DEPO-TESTOSTERONE (testosterone cypionate) injection, solution — Prescribing Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39
Turner L, Ly LP, Desai R, et al. Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. J Endocr Soc. 2019;3(8):1531-1540. https://pmc.ncbi.nlm.nih.gov/articles/PMC6676071/
Spratt DI, Stewart II, Savage C, et al. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients. J Clin Endocrinol Metab. 2017;102(7):2349-2355. https://pubmed.ncbi.nlm.nih.gov/28379417/
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. https://pmc.ncbi.nlm.nih.gov/articles/PMC4721027/